Biomics Biopharma Limited (the Company) is the ultimate parent company of the Biomics Group.
The Company’s wholly owned subsidiary, Biomics Biotechnologies Co., Ltd (Biomics), was incorporated in 2006 in the People’s Republic of China (PRC). Biomics is a near-clinical-stage biopharmaceutical company in developing and commercialising double stranded ribonucleic acid (dsRNA) based innovative products for unmet medical needs.
As early as the early-mid 2000s, the Company’s scientific founders were leaders in the field of small interfering RNA (siRNA) library construction, drug delivery and liposome formulation and production in USA. In 2012, the world’s first RNAi-based marketed product, Britena for skin depigmentation, was launched by Genecon Biotechnologies Co., Ltd., a joint venture company in which Biomics then had a 49% interest. In 2015, the Group launched its first RNAi-based skincare product, CoSensia, for acne. Since its establishment the Group has invested over $11 million in research and development. The Company believes that now is the appropriate time to maximise the CoSensia opportunity in China and globally, and at the same time advance its Hepatitis B virus (HBV) therapeutic program to the clinical proof of concept stage.
The Company is managed by a team of experienced and highly skilled professionals, including several senior scientists who have returned to China following extensive periods working in life sciences companies based in North America.
The Biomics Group is based in the National Economic and Technological Development Zone of Nantong, Jiangsu, People’s Republic of China, about 1.5 hours drive from Shanghai City. The Company’s well-equipped 10,000 square meters Good Manufacturing Practice (GMP) compliant R&D facility contains a comprehensive RNAi drug development platform which comprises entire siRNA target libraries, high-throughput screening, large-scale synthesis, siRNA delivery system and in vivo evaluation models. The facility is located on a land of approximately 16.5 acres.
The Company’s intellectual property portfolio consists of over 30 patents and patent applications forming a strong foundation for the Biomics’ business objectives.